Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib

Julie Schneider; Ann Schalenbourg; Jean Dudler; Yan Guex-Crosier

doi:10.1055/a-1766-6739

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2022; 239(04): 572-574
DOI: 10.1055/a-1766-6739

Der interessante Fall

Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib

Intermediäre Uveitis bei einem HLA-B27-positiven Patienten, der mit Upadacitinib behandelt wurde

Authors

Julie Schneider

¹Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland
Ann Schalenbourg

¹Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland
Jean Dudler

²Department of Rheumatology, HFR, Fribourg, Switzerland
Yan Guex-Crosier

¹Ophthalmology, Hôpital ophtalmique Jules-Gonin, University of Lausanne, Lausanne, Switzerland

Abstract

Full Text

References

References
1 Van der Heijde D, Song IH, Pangan AL. et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet 2019; 394: 2108-2117
2 Smolen JS, Pangan AL, Emery P. et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet 2019; 393: 2303-2311
3 Mease PJ, Lertratanakul A, Anderson JK. et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 2020; 80: 312-320
4 Guttman-Yassky E, Thaçi D, Pangan AL. et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol 2020; 145: 877-884
5 Dodds EM, Lowder CY, Meisler DM. Posterior segment inflammation in HLA-B27+ acute anterior uveitis: clinical characteristics. Ocul Immunol Inflamm 1999; 7: 85-92
6 Heimann H, Bornfeld N, Vij O. et al. Vasoproliferative tumours of the retina. Br J Ophthalmol 2000; 84: 1162-1169
7 Bing SJ, Lyu C, Xu B. et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis 2020; 26: 641-651
8 Bauermann P, Heiligenhaus A, Heinz C. Effect of Janus Kinase Inhibitor Treatment on Anterior Uveitis and Associated Macular Edema in an Adult Patient with Juvenile Idiopathic Arthritis. Ocul Immunol Inflamm 2019; 27: 1232-1234
9 Paley MA, Karacal H, Rao PK. et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep 2018; 13: 53-55
10 Miserocchi E, Giuffrè C, Cornalba M. et al. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol 2020; 39: 847-851